Hemab Therapeutics Holdings, Inc. (COAG)
NASDAQ: COAG · Real-Time Price · USD
29.24
0.00 (0.00%)
Jun 18, 2026, 4:00 PM EDT - Market closed
COAG Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, COAG stock has a consensus rating of "Strong Buy" and an average price target of $41.75. The average 1-year stock price forecast is 42.78% higher than the current stock price, while the lowest is $36 (+23.12%) and the highest is $50 (+71.00%).
Price Target: $41.75 (+42.78%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for COAG stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 |
|---|---|---|
| Strong Buy | 4 | 4 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
| Total | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Buy Maintains $39 | Buy | Maintains | $39 | +33.38% | Jun 8, 2026 |
| Evercore ISI | Evercore ISI | Buy Initiates $50 | Buy | Initiates | $50 | +71.00% | May 26, 2026 |
| Wedbush | Wedbush | Buy Initiates $42 | Buy | Initiates | $42 | +43.64% | May 26, 2026 |
| Goldman Sachs | Goldman Sachs | Buy Initiates $36 | Buy | Initiates | $36 | +23.12% | May 26, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-3.06
EPS Next Year
-2.45
from -3.06
EPS and Forward PE are based on non-GAAP adjusted numbers.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | n/a | ||
| Avg | n/a | ||
| Low | n/a |
Revenue Growth
| Revenue Growth | 2027 | 2028 |
|---|---|---|
| High | - | |
| Avg | - | |
| Low | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -2.48 | ||
| Avg | -3.06 | ||
| Low | -3.59 |
EPS Growth
| EPS Growth | 2027 | 2028 |
|---|---|---|
| High | - | |
| Avg | - | |
| Low | - |